Abstract
Introduction: Until the end of July 2015 reimbursement of interferon-free treatment regimens for chronic hepatitis C was limited to patients with advanced liver fibrosis (F3 and F4) and to patients with severe extrahepatic manifestations. Since August 2015 treatment coverage was extended to include F2. In order to qualify for reimbursement liver disease has to be staged by Fibroscan®, biopsy or clinical findings. Furthermore, treatment can only be performed at selected specialized hospitals. The aim of this analysis was to assess the percentage of patients eligible for interferon-free regimens and the impact of extending insurance coverage to F2.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
